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ABSTRACT
Introduction: Diabetes-associated autoantibodies (DAA) is the hallmark of T1DM and LADA which are frequently 
tested in young diabetes patients. It was noted that up to 10-15% of patients with initial diagnosis of T2DM also 
exhibit DAA. Regardless of the classification, the presence of DAA suggests an underlying islet autoimmunity which 
lead to progressive pancreatic β-cell failure. There is limited data reported on DAA in young diabetes patients in 
Malaysia. This study aims to determine the frequency of DAA positivity and its association with demographic and 
clinical characteristics among this cohort. Methods: A retrospective study using secondary data obtained from Al-
lergy and Immunology Research Centre, Institute for Medical Research, Malaysia. This study included 194 diabetes 
patients who were diagnosed before the age of 40 years old and tested for GADA, ICA, IA2A and IAA. Results: From 
194 patients, 91 (46.9%) were positive for least one of the following DAA: ICA (79, 40.7%), GADA (61, 31.4%), IA2A 
(37, 19.1%) and IAA (9, 4.6%). Multiple positivity was higher (73.6%) compared to single positivity. Highest com-
bination of double positivity was ICA+GADA (54, 59.3%) and triple positivity was ICA+GADA+IA2A (25, 27.5%). 
Simultaneous positivity of four autoantibodies was seen in only one (1.1%) patient. ICA, GADA and IA2A were asso-
ciated with age group and ethnicity (all p < 0.001). Only IA2A was associated with gender (p = 0.012). Conclusions: 
GADA, ICA ad IA2A are more significant in young Malaysian diabetes patients. IAA has a very low frequency in this 
studied population.
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INTRODUCTION
Prevalence of diabetes mellitus in Malaysia is among 
the highest in the world. It was reported to be 17.5% 
in 2015, almost 6% increment from the last 10 years 
(1). As reported world-wide, the incidence of diabetes 
is increasing especially in adolescent and young adults 
(2–4). Diabetes-associated autoantibodies (DAA) are 
produced following autoimmune β-cell injury and are 
frequently tested in young DM patients. Apart from 
confirming type 1 diabetes mellitus (T1DM), it helps to 
differentiate T1DM from type 2 diabetes mellitus (T2DM) 
especially with non-typical or overlapping phenotypes 
(5).  
Islet cell cytoplasmic antibodies (ICA), glutamic 
acid decarboxylase antibodies (GADA), insulinoma-
associated-2 autoantibodies (IA2A) and insulin 
autoantibodies (IAA) are four commonly measured 
diabetes autoantibodies.  Although the appearance of 
these autoantibodies does not follow a distinct pattern, the 
presence of multiple autoantibodies is highly predictive 
of T1DM (6). Diabetes-associated autoantibodies were 
also found to be positive in up to 10-15% of patients 
initially diagnosed with T2DM (7–9). This subgroup of 
patients are classified as latent autoimmune diabetes in 
adults (LADA). LADA is also called as double diabetes 
or type 1.5 diabetes as it has features of T2DM with 
positive DAA. LADA with multiple autoantibodies was 
shown to progress into β-cell failure earlier than those 
with single autoantibody positivity (10). 
Identifying the presence of DAA enables proper 
classification of diabetes and is clinically relevant for 
management. Positive autoantibodies indicates ongoing 
β-cell injury and earlier needs for insulin treatment 
compared to those with absent autoantibodies (11). 
This group of patients is likely to respond poorly to 
oral hypoglycaemic agents which results in poor 
blood glucose control (12). An ideal therapeutic aim 
in autoimmune diabetes would be at protecting the 
residual β-cell mass and function (13). The prevalence of 
DAA are reported to be different with different cohort of 
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patients (14). Till date, it is still unclear whether specific 
combinations of different autoantibodies is associated 
with certain forms of diabetes or carries certain risks (6). 
There are many studies involving DAA but the 
information on young diabetes patients in Asia, 
particularly in Malaysia is limited (15,16). This study 
aims to determine the   presence of four classical DAA 
(ICA, GADA, IA2A and IAA) and their association with 
demographic and clinical characteristics among young 
DM patients in Malaysia. 
MATERIALS AND METHODS
This is a retrospective study using data collected from 
Allergy and Immunology Research Centre (AIRC), 
Institute for Medical Research, Malaysia which is the 
reference laboratory for specialised autoimmune tests. 
The study included 194 patients (111 females and 83 
males) who were diagnosed with DM before the age of 
40 years old with varying disease duration. All patient 
samples were analysed for the four classical DAA 
(GADA, ICA, IA2A and IAA). The relevant demographic 
and clinical characteristics (age, ethnicity, gender, 
disease duration and HbA1c level) were obtained from 
the laboratory request forms. The results of DAA testing 
were collected from the laboratory information system 
(LIS) in AIRC. This study protocol was approved by the 
Malaysia Ministry of Health ethics committee (NMRR-
16-757-30464).
Anti-glutamic acid decarboxylase (GADA), anti-islet 
cell (ICA), anti-insulinoma associated antigen 2 (IA2A) 
and anti-insulin (IAA) were assayed by enzyme-linked 
immunosorbent assay (ELISA) (MEDIPAN Medizym®, 
Germany). The cut-off positivity was according to 
manufacturer’s recommendation which were 5 IU/ml 
for GADA, 1.0 for ICA, 10 IU/ml for IA2A and 18 IU/
ml for IAA.
Statistical analysis was performed with Social Package 
for Social Science Version 25.0. The associations 
were tested using Chi-square test or Fisher’s exact test. 
Comparison between groups were analysed using Mann-
Whitney U test and Kruskal-Wallis test. The correlations 
were analysed using Pearson’s correlation coefficient 
test. The level of significance was set at p value of less 
than 0.05.
RESULTS  
The overall demographic characteristics of patients are 
shown in Table I. In summary, 91 (46.9%) patients aged 
between 10 to 20 years old. Only 21 (10%) patients aged 
below 10 years old. Most were of Malay ethnicity, 129 
(66.5%) with slight female predominance, 111 (57.2%). 
Majority of patients, 144 (74.2%) were diagnosed of 
having DM in less than a year and 184 (94.8%) had 
raised HbA1c level. 
Table I: Demographic and clinical characteristics of young diabetes 
patients in Malaysia
Demographic and clinical character-
istics
Patients (n = 194)
Frequency (n) Percentage (%)
Age Group
19.14 ± 8.413a 
(years)
<10 years
10-20 years
20-30 years
>30 years
21
91
57
25
10.8
46.9
29.4
12.9
Gender Male
Female
83
111
42.8
57.2
Ethnicity Malay
Chinese
Indians
Others
129
26
29
10
66.5
13.4
14.9
5.2
Disease duration
22.30 ± 46.08a
(months)
< 1 year
1 - 5 years
> 5 years
127
43
24
65.5
22.2
12.4
HbA1c level
11.40 ± 2.96a
(%)
≤ 6.5%
> 6.5%
11
183
5.7
94.3
a Mean ± SD
Positivity of diabetes autoantibodies and their 
combination
Among 194 patients, 91 (46.9%) had at least one 
positive DAA. ICA was found to be positive in up to 
79 (40.7%) of patients, followed by GADA, 61 (31.4%) 
and IA2A, 37 (19.1%). IAA was found to be positive in 
only 9 (4.6%) patients (Table II). Among patients with 
positive autoantibodies, 24 (26.4%) had single positivity 
compared to multiple positivity, 67 (73.6%). For double 
positivity, combination of ICA + GADA was the highest 
as seen in 54 (59.3%) patients. Triple positivity of DAA 
was found to be highest with ICA + GADA + IA2A 
combination in 25 (27.5%) of patients. Simultaneous 
positivity of four autoantibodies was observed in only 
one (1.1%) patient. 
Table II: Diabetes-associated autoantibodies and their combinations 
in young diabetes patients with positive autoantibodies
DAA or its combination Patients with positive DAA (n=91)
Frequency (n) Percentage (%)
ICA 79 86.8
GADA 61 67.0
IA2A 37 40.7
IAA 9 9.9
ICA + GADA 54 59.3
ICA + IA2A 33 36.3
ICA + IAA 5 5.5
GADA + IA2A 27 29.7
GADA + IAA 4 4.4
IA2A + IAA 1 1.1
ICA + GADA + IA2A 25 27.5
ICA + GADA + IAA 3 3.3
ICA + IA2A + IAA 1 1.1
GADA + IA2A + IAA 1 1.1
ICA + GADA + IA2A + IAA 1 1.1
ICA / GADA / IA2A / IAA 91 -
DAA, diabetes-associated autoantibodies; ICA, islet cell cytoplasmic antibodies; GADA, glu-
tamic acid decarboxylase antibodies; IA2A, insulinoma-associated-2 autoantibodies; IAA, in-
sulin autoantibodies; “+” indicates simultaneous positivity; “/” indicates at least one positivity
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Association of diabetes autoantibodies
Diabetes-associated autoantibodies were found to be 
associated with demographic characteristics (Table 
III). ICA, GADA and IA2A were associated with age 
group and ethnicity (all p < 0.001). However, only 
IA2A was associated with gender (p = 0.012). All the 
autoantibodies were neither associated with disease 
duration nor HbA1c level.
Table III: Association of diabetes-associated autoantibodies with de-
mographic and clinical characteristics of young diabetes patients
Patients (n = 194)
ICA IAA GADA IA2A
Positivity n (%) 79 (40.7%) 9 (4.6%) 61 (31.4%) 37 (19.1%)
Age
   < 10 18 3 16 12
   10 - 20 32 3 26 13
   20 - 30 22 2 15 9
   > 30 7 1 4 3
X2  (df)a 20.56 (3) NA 23.32 (3) NA
p value < 0.001 0.183b < 0.001 < 0.001b
Gender
   Male 30 5 25 9
   Female 49 4 36 28
X2  (df)a
p value
1.26 (1)
p=0.262
NA
p=0.501b
0.12 (1)
p=0.731
6.36 (1)
p=0.012
Ethnicity
   Malay 40 6 21 12
   Chinese 14 1 12 9
   Indians 15 2 15 12
   Others 7 0 3 4
X2  (df)a 15.92 (3) NA 11.44 (3) NA
p value 0.001 0.915b 0.001 < 0.001b
Disease dura-
tion
   < 1 year 46 7 41 29
   1 - 5 years 21 2 12 5
   > 5 years 12 0 8 3
3.10 (2) NA 0.33 (2) 3.38 (2)
0.213 0.770b 0.848 0.184
HbA1c level
   ≤ 6.5% 76 8 60 37
   > 6.5% 3 1 1 0
X2  (df) NA NA NA NA
p value 0.598b 0.287b 0.463b 0.350b
DAA, diabetes-associated autoantibodies; ICA, islet cell cytoplasmic antibodies; GADA, glu-
tamic acid decarboxylase antibodies; IA2A, insulinoma-associated-2 autoantibodies; IAA, 
insulin autoantibodies
a Chi-square test         b Fisher’s exact test 
Comparison of diabetes autoantibodies level 
Levels of ICA, GADA and IA2A were significantly 
higher in patients below 10 years old compared to other 
age groups. Levels of ICA (p = 0.002) and GADA (p = 
0.005) were significantly higher in Chinese compared 
to Malays whereas ICA (p = 0.001) was significantly 
higher in Indians compared to Malays (Table IV). There 
Table IV: Comparison of diabetes-associated autoantibodies levels 
with demographic and clinical characteristics of young diabetes pa-
tients
Median (IQR)
ICA
(ratio)
IAA
(U/mL)
GADA
(IU/mL)
IA2A
(IU/mL)
Age
   < 10 years 14.86 
(11.20)
2.11 (8.90) 107.14 
(243.40)
72.76 
(198.54)
   10 – 20 years 0.49 (2.75) 2.06 (2.40) 2.87 (6.13) 0.69 (4.98)
   20 – 30 years 0.66 (4.38) 1.86 (2.74) 2.47 (5.45) 0.01 (7.50)
   > 30 years 0.42 (1.71) 1.77 (5.04) 2.86 (3.84) 0.52 (1.49)
df a 3 3 3 3
p value < 0.001 0.685 < 0.001 0.007
Gender
   Male 0.48 (2.83) 1.81 (2.54) 3.01 (15.55) 0.01 (1.09)
   Female 0.60 (5.82) 2.02 (2.92) 2.78 (17.25) 1.04 (13.34)
Z-statisticb
p value
-1.149
p=0.136b
-1.234
p=0.217b
-0.591
p=0.555b
-2.433
p=0.015b
Ethnicity
   Malay 0.43 (1.80) 2.02 (2.55) 2.77 (4.43) 0.08 (3.13)
   Chinese 1.77 
(16.55)
1.70 (2.62) 4.29 
(248.22)
0.65 (80.15)
   Indians 4.21 
(14.13)
1.85 (4.54) 10.64 
(93.49)
0.66 (144.57)
   Others 1.68 (7.51) 3.44 (4.45) 2.84 (5.85) 4.15 (94.12)
dfa 3 3 3 3
p value < 0.001 0.714 0.023 <0.130
Disease dura-
tion
   < 1 year 0.51 (8.24) 1.85 (2.63) 2.92 (15.53) 0.77 (7.79)
   1 - 5 years 0.88 (6.21) 2.19 (2.66) 2.45 (13.10) 0.01 (3.10)
   > 5 years 0.99 (2.70) 1.83 (3.84) 3.52 (26.03) 0.69 (2.05)
df a 2 2 2 2
p value 0.592 0.387 0.113 0.120
HbA1c level
   ≤ 6.5% 0.48 (2.75) 2.46 
(14.28)
3.24 (4.56) 1.02 (7.66)
   > 6.5% 0.54 (7.67) 1.86 (2.89) 2.87 (16.07) 0.54 (7.22)
Z-statisticb -0.007 -1.443 -0.169 -0.188
p value 0.995b 0.149b 0.866b 0.851b
DAA, diabetes-associated autoantibodies; ICA, islet cell cytoplasmic antibodies; GADA, glu-
tamic acid decarboxylase antibodies; IA2A, insulinoma-associated-2 autoantibodies; IAA, 
insulin autoantibodies
a Kruskal-Wallis test        b Mann-Whitney U test 
were no significant difference between DAA levels with 
disease duration and HbA1c.
Correlation of diabetes autoantibodies 
Higher levels of DAA were seen in younger patients. All 
four autoantibody levels were inversely correlated with 
age (Table V).
  
DISCUSSION
The classification of diabetes mellitus is not as straight 
forward as previously thought. Although they are mainly 
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compared to GADA in a study conducted by Trisorus et 
al. on Thai juvenile-onset T1DM (23), but an opposite 
finding was found from another study by Anderson et 
al. carried out in Sweden population (31). Buzzetti et 
al. concluded that IA2A appearance was associated 
with DM patients of high BMI, which phenotypes were 
similar to T2DM (21). It is suggesting that a different 
mechanism of DM pathogenesis might be involved in 
this group of patients.
Presence of multiple DAA is associated with more rapid 
progression of β-cell failure (32). It is also more significant 
and better at predicting the risk of developing T1DM as 
compared to single autoantibody positivity. However, 
these autoantibodies are not completely independent of 
each other and they are shown to have age relationship 
(6). In our study, there were 67 (73.6%) patients who 
had multiple autoantibodies. Double positivity was 
found to be highest with ICA + GADA combination that 
was in 54 (59.3%) patients. Triple positivity was found 
to be the highest with ICA + GADA + IA2A combination 
that was in 25 (27.5%) patients. Simultaneous positivity 
of four autoantibodies was observed in only one (1.1%) 
patient. Multiple DAA positivity is reported to be more 
commonly seen in T1DM children below 10 years old 
(33) and prevalence significantly decrease along the 
disease duration (22). A study in elderly with T2DM 
demonstrated that majority tend to have single DAA 
positivity (34). 
In this study, ICA, GADA and IA2A were shown to be 
associated with age group. Their levels were significantly 
higher in children less than 10 years old as compared to 
older age groups. Previous studies have found that the 
positivity of DAA varies with age of onset. GADA and 
IA2A were shown to significantly decrease along disease 
duration (22,35). Our study did not show association of 
IAA with age. This finding might have been contributed 
by the low number of patients that aged below 10 years 
old (10.8%) and the overall low IAA positivity in this 
cohort (4.6%). IAA positivity inversely correlated with 
age and is rare in adults. Its positivity decreases from 
50-60% in T1DM patients aged less than 10 years old 
to only 10% in above 30 years old. This is in contrast 
to IA2A positivity which gradually decreases following 
disease duration and GADA positivity which is shown to 
be the most consistent regardless of age (36,37). GADA 
was also shown to be persistently positive in about 35% 
of LADA patients after 3 years (38).  
There was no significant difference in the number of 
young DM patients according to gender in our cohort. 
However, IA2A was found to be associated with gender 
and its level was significantly higher in females. Several 
studies have reported GADA and IA2A to be more 
frequent in females, but the significant higher levels 
were only seen in GADA (22,36,39,40).
The prevalence of DAA varies in different populations. 
Table V: Correlation of diabetes-associated autoantibodies with age
Age
ra p value
ICA -0.172 0.016
IAA -0.152 0.034
GADA -0.186 0.010
IA2A -0.213 0.003
ICA, islet cell cytoplasmic antibodies; GADA, glutamic acid decarboxylase antibodies; IA2A, 
insulinoma-associated-2 autoantibodies; IAA, insulin autoantibodies
a Spearman’s rank correlation coefficient
classified into T1DM and T2DM, diabetes mellitus is more 
a spectrum of heterogenous disease (17). Certain clinical 
features of T2DM such as overweight and acanthosis 
nigricans are seen in up to 12-14% of T1DM patients 
(18). Increasing prevalence of obesity in children and 
adolescent has made identifying the types of diabetes 
challenging (19,20). The proportion of patients who 
were clinically T2DM, but later found out to be adult-
onset T1DM or LADA falls in between 6.5-15% (21). 
DM with underlying autoimmune mechanism imposes 
different clinical and public health implications. Testing 
for DAA is not only for confirming T1DM and LADA, 
but is also helpful for ascertaining the classification of 
diabetes mellitus with mixed phenotypes. Presence of 
DAA indicates continuous injury that will progress into 
β-cell failure and future needs of insulin administration 
(18,22).
Diabetes-associated autoantibodies was found to be 
positive in 91 (46.9%) young (40 years old and below) 
Malaysians with diabetes mellitus, regardless of the 
form. ICA has the highest frequency of positivity which 
was seen in 76 (40.7%) patients, followed by GADA in 
61 (31.4%) patients. Generally, ICA and GADA were 
positive in 70-80% of T1DM and 10-20% of T2DM (23–
25). ICA was the first autoantibodies recognised to be 
associated with autoimmune form of diabetes mellitus 
back in 1970s (26–28). Subsequent studies had revealed 
that ICA are heterogeneous and target multiple antigens 
including GAD65, IA-2 and IA-2β. GADA which is 
directed against GAD65 was shown to be part of positive 
ICA reaction (6,26). According to the Islet Autoantibody 
Standardization Program (IASP), they recommend four 
types of DAA measurement which are GADA, IA-
2A, IAA and zinc transporter 8 autoantibody (ZnT8A) 
(29,30). ICA has been very useful and is still measured 
in some laboratories including in Malaysia, but many 
have opted for autoantibodies to specific proteins of the 
islet cells. As reported by Decochez et al., (37) and our 
current study, it can be concluded that ICA and GADA 
positivity are almost similar in frequency.
IA-2A was only found in 37 (9.1%) patients which is not 
in agreement with a study conducted by Ong et al. on 
Singaporean adult-onset diabetes. That study concluded 
that IA-2A is more prevalent than GADA in Asian cohort 
compared to Caucasian (14). However, inconsistent 
findings on IA2A were found in the following studies 
(23,31). IA-2A was noted to be of lower prevalence 
Mal J Med Health Sci 16(2): 118-125, May 2020 122
These differences were seen within the same continents 
such as among the European countries as reported in 
studies by Garnier et al. on a large French cohort (47), 
by Decochez et al. on Belgian population (37) and 
by Anderson et al. on Swedish population (31).  Such 
differences were also seen among different ethnicities 
in Asians as reported by several studies on DM patients 
in China (7), Thailand (18, 23), Korea (35), Taiwan (22) 
and Malaysia (16). We found that ICA to be significantly 
higher in Malaysian Chinese compared to Malays and 
Indians. GADA on the other hand was only significantly 
higher in Chinese compared to Malays. Our finding is 
in contrast to a study among adult Singaporean cohort 
which concluded that GADA is less prevalent in Asian 
compared white European cohort (14). 
GADA was found to be present in 77.1% of multi-ethnic 
DM patients between 12 to 40 years old from China, 
India, Malaysia and Singapore as reported in a study by 
Thai et al. (15). Other studies on paediatric and young 
DM patients in Thailand, Taiwan and Korea also found 
similar percentages of GADA positivity which were 
in between 65.0% to 75.0% (18,22-23,35). However, 
GADA positivity in Malaysian young DM patients were 
lower as seen in our study (31.4%) which also agrees 
to what was reported by Nazaimoon et al. in year 2000 
(33.8%) (16). 
The frequency of positive IAA is the lowest in our study 
and it does not associate with all the demographic 
and clinical characteristics studied.  Wang et al. have 
concluded that IAA is often the first autoantibody 
detected in children at diagnosis (41). This finding was 
also supported by Larrson et al. and Bosi et al. (42,43). 
Although insulin is regarded to be a highly specific 
antigen of β-cells, IAA measures both antibodies against 
endogenous and exogenous insulin and becomes 
clinically insignificant after insulin treatment is initiated 
(44,45). 
 
We found no relationship between the levels of DAA 
and HbA1c. This finding is in agreement with a study 
looking at the association between GADA and clinical 
severity of fulminant T1DM where GADA was shown to 
be correlated with blood pH and ketone bodies, but not 
HbA1c (46). Another study also concluded that GADA 
and IAA levels were not correlated with HbA1c levels 
(35).
Another interesting part is that more than half of this 
study cohort were negative for all four DAA tested. As 
reported in previous studies, it can be concluded that 
not all autoimmune DM patients will be tested positive 
for the currently available DAA assays (14-16,22-24,47). 
They might produce autoantibodies against other not 
tested epitopes such as ZnT8. Anti-ZnT8 was found to 
be positive in 5-10% of T1DM patients (47–49) and 
3-12% of LADA patients whom initially diagnosed as 
T2DM with negative GADA and IA2A (38). There is 
also possibility of the autoantibodies to be directed at 
other islet cell epitopes that are yet to be discovered. 
Another possibility is that these young DM patients are 
truly having earlier than usual onset of T2DM (19) or 
having rarer monogenic disorders of DM like maturity-
onset diabetes of the young (MODY) (50).
Our study has a few limitations. We did not classify the 
diagnosis of diabetes according to the classification. 
Rather, the data was analysed in relation to young DM 
patients of less than 40 years old in general. It is also 
of note that the sensitivity of ELISA techniques varies 
among different kits and reports. This might explain the 
differences in the findings among different studies. The 
different positivity cut-off values could also contribute 
to these variation. The strength of this study is that it 
analysed the four classical DAA in young DM patients 
from all over Malaysia, thus representing the multi-
ethnic Asian population in this country. 
Information on different frequency of DAA in local 
population provides useful reference for selection of 
types of DAA to be tested. Taking the most common 
DAA to be present and cost into consideration, a superior 
DAA combination can be determined. GADA is islet cell 
protein specific, in contrast to ICA but has almost similar 
positivity rate with the latter. IA2A is also substantial as 
its positivity rate is more than half of GADA frequency 
in studied population. IAA positivity on the other hand 
is very low in Malaysian young DM patients. Apart from 
GADA and IA2A, it might be beneficial to consider 
other specific autoantibodies such as anti-ZnT8 in order 
to increase the detection rate of autoimmune DM. 
Additional study is needed to assess the performance of 
a new DAA combination in this population.
CONCLUSION
Autoimmune diabetes mellitus has a distinct pathological 
mechanism and is best detected by measuring the 
diabetes-associated autoantibodies. Serum ICA, GADA 
and IA2A are significantly associated with certain 
demographic and clinical characteristics of young 
Malaysian DM patients. Serum IAA on the other hand 
has a very low frequency and is less useful in detecting 
autoimmune DM in studied population. 
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